NASDAQ:KYTH - Kythera Biopharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Kythera Biopharmaceuticals (NASDAQ:KYTH)

Kythera Biopharmaceuticals logoKYTHERA Biopharmaceuticals, Inc. (KYTHERA) is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company's initial focus is on the facial aesthetics market. The Company's product candidate is ATX101, an injectable drug in late-stage clinical development for the treatment of submental fullness associated with submental fat, which commonly presents as an undesirable double chin. ATX101 is a formulation of a purified synthetic version of deoxycholic acid. The Company has completed Phase III clinical trials for ATX101 and has made regulatory filings outside the United States, in Canada, Switzerland and Australia.

Receive KYTH News and Ratings via Email

Sign-up to receive the latest news and ratings for KYTH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-12,900.69%
Return on Equity-93.97%
Return on Assets-72.56%


Outstanding SharesN/A

Kythera Biopharmaceuticals (NASDAQ:KYTH) Frequently Asked Questions

What is Kythera Biopharmaceuticals' stock symbol?

Kythera Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KYTH."

How were Kythera Biopharmaceuticals' earnings last quarter?

Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) issued its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.10) by $0.34. The biopharmaceutical company earned $288 million during the quarter. Kythera Biopharmaceuticals had a negative return on equity of 93.97% and a negative net margin of 12,900.69%. View Kythera Biopharmaceuticals' Earnings History.

Has Kythera Biopharmaceuticals been receiving favorable news coverage?

Media headlines about KYTH stock have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Kythera Biopharmaceuticals earned a news sentiment score of 0.19 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 47.20 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Kythera Biopharmaceuticals?

Shares of KYTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Kythera Biopharmaceuticals?

Kythera Biopharmaceuticals' mailing address is 27200 Agoura Rd Ste 200, AGOURA HILLS, CA 91301-5127, United States. The biopharmaceutical company can be reached via phone at +1-818-5874500.

MarketBeat Community Rating for Kythera Biopharmaceuticals (KYTH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  67 (Vote Outperform)
Underperform Votes:  58 (Vote Underperform)
Total Votes:  125
MarketBeat's community ratings are surveys of what our community members think about Kythera Biopharmaceuticals and other stocks. Vote "Outperform" if you believe KYTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KYTH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Kythera Biopharmaceuticals (NASDAQ:KYTH) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 5/22/2016 forward)


Kythera Biopharmaceuticals (NASDAQ:KYTH) Earnings History and Estimates Chart

Earnings by Quarter for Kythera Biopharmaceuticals (NASDAQ:KYTH)

Kythera Biopharmaceuticals (NASDAQ KYTH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2015Q2($1.10)($1.44)$288.00 millionViewN/AView Earnings Details
5/7/2015Q1 2015($1.11)($1.24)ViewN/AView Earnings Details
3/2/2015Q414($1.07)($1.07)ViewN/AView Earnings Details
11/10/2014Q3 2014($0.93)($0.99)ViewN/AView Earnings Details
8/7/2014Q2($0.83)($0.86)ViewListenView Earnings Details
5/8/2014Q1($0.67)($0.76)ViewListenView Earnings Details
3/17/2014Q413($0.69)($0.66)ViewN/AView Earnings Details
11/14/2013Q3 2013($0.74)($0.62)ViewN/AView Earnings Details
8/6/2013Q2 2013($0.70)($0.67)ViewN/AView Earnings Details
5/13/2013Q1 2013($0.97)($0.77)ViewN/AView Earnings Details
3/21/2013Q4 2012($0.76)($1.04)ViewN/AView Earnings Details
11/13/2012Q312($11.41)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Kythera Biopharmaceuticals (NASDAQ:KYTH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Kythera Biopharmaceuticals (NASDAQ KYTH) Insider Trading and Institutional Ownership History

Insider Trading History for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Insider Trading History for Kythera Biopharmaceuticals (NASDAQ:KYTH)

Kythera Biopharmaceuticals (NASDAQ KYTH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/24/2015Frederick Beddingfield IIIinsiderSell110,638$74.91$8,287,892.58View SEC Filing  
9/24/2015John W. SmitherCFOSell53,835$74.90$4,032,241.503,368View SEC Filing  
9/23/2015Elisabeth SandovalinsiderSell83,122$74.90$6,225,837.80View SEC Filing  
9/23/2015Keith KleinGeneral CounselSell52,153$74.90$3,906,259.704,068View SEC Filing  
9/22/2015John W. SmitherCFOSell6,645$74.91$497,776.953,368View SEC Filing  
9/22/2015Keith KleinGeneral CounselSell10,589$74.90$793,116.104,068View SEC Filing  
9/18/2015John W. SmitherCFOSell1,054$74.95$78,997.303,368View SEC Filing  
9/1/2015Camille D SamuelsDirectorSell250$74.72$18,680.0013,685View SEC Filing  
6/25/2015Frederick Beddingfield IIIInsiderSell30,583$75.66$2,313,909.78View SEC Filing  
6/25/2015John W SmitherCFOSell4,600$75.50$347,300.00View SEC Filing  
5/1/2015Keith R LeonardCEOSell13,000$44.93$584,090.00View SEC Filing  
4/30/2015Elisabeth SandovalInsiderSell1,654$45.55$75,339.70View SEC Filing  
4/30/2015John W SmitherCFOSell2,041$45.49$92,845.09View SEC Filing  
4/30/2015Keith R LeonardCEOSell5,557$45.29$251,676.53View SEC Filing  
4/15/2015Keith R LeonardCEOSell2,709$50.52$136,858.68View SEC Filing  
4/1/2015Keith R LeonardCEOSell13,548$48.14$652,200.72View SEC Filing  
3/16/2015Keith R LeonardCEOSell5,312$50.16$266,449.92View SEC Filing  
3/9/2015Nathaniel E DavidDirectorSell6,185$55.00$340,175.00View SEC Filing  
3/5/2015John W SmitherCFOSell4,200$48.09$201,978.00View SEC Filing  
3/5/2015Nathaniel E DavidDirectorSell12,375$48.49$600,063.75View SEC Filing  
3/2/2015Keith R LeonardCEOSell10,625$40.94$434,987.50View SEC Filing  
3/2/2015Nathaniel E DavidDirectorSell1,875$40.78$76,462.50View SEC Filing  
2/18/2015John W SmitherCFOSell2,000$41.00$82,000.00View SEC Filing  
2/17/2015Keith R LeonardCEOSell4,165$40.46$168,515.90View SEC Filing  
2/2/2015Keith R LeonardCEOSell6,249$36.70$229,338.30View SEC Filing  
2/2/2015Nathaniel E DavidDirectorSell1,715$36.76$63,043.40View SEC Filing  
1/29/2015John W SmitherCFOSell1,000$38.00$38,000.00View SEC Filing  
1/23/2015John W SmitherCFOSell3,000$35.65$106,950.00View SEC Filing  
1/16/2015Camille D SamuelsDirectorSell250$36.70$9,175.00View SEC Filing  
1/2/2015Keith R LeonardCEOSell6,120$35.37$216,464.40View SEC Filing  
1/2/2015Nathaniel E DavidDirectorSell1,680$35.30$59,304.00View SEC Filing  
12/1/2014Keith R LeonardCEOSell5,994$37.60$225,374.40View SEC Filing  
12/1/2014Nathaniel E DavidDirectorSell1,645$37.67$61,967.15View SEC Filing  
11/3/2014Keith R LeonardCEOSell5,865$34.95$204,981.75View SEC Filing  
11/3/2014Nathaniel E DavidDirectorSell1,610$34.90$56,189.00View SEC Filing  
10/23/2014Keith R LeonardCEOSell1,913$35.13$67,203.69View SEC Filing  
10/1/2014Keith R LeonardCEOSell3,826$32.55$124,536.30View SEC Filing  
10/1/2014Nathaniel E DavidDirectorSell1,350$32.60$44,010.00View SEC Filing  
9/2/2014Nathaniel E DavidDirectorSell1,540$37.37$57,549.80View SEC Filing  
8/4/2014Keith R LeonardCEOSell1,828$35.10$64,162.80View SEC Filing  
8/4/2014Nathaniel E DavidDirectorSell1,505$33.08$49,785.40View SEC Filing  
8/1/2014Keith R LeonardCEOSell3,656$32.80$119,916.80View SEC Filing  
7/2/2014John W SmitherCFOSell2,250$40.00$90,000.00View SEC Filing  
7/2/2014Keith R LeonardCEOSell8,925$39.47$352,269.75View SEC Filing  
7/2/2014Nathaniel E DavidDirectorSell1,778$39.20$69,697.60View SEC Filing  
6/16/2014Keith R LeonardCEOSell1,743$36.58$63,758.94View SEC Filing  
6/2/2014Keith R LeonardCEOSell3,486$32.54$113,434.44View SEC Filing  
6/2/2014Nathaniel E DavidDirectorSell1,230$32.56$40,048.80View SEC Filing  
5/1/2014Keith LeonardCEOSell3,400$32.56$110,704.00View SEC Filing  
5/1/2014Nathaniel DavidDirectorSell1,200$32.60$39,120.00496,085View SEC Filing  
4/1/2014Jeffrey WebsterVPSell4,000$39.36$157,440.00View SEC Filing  
4/1/2014Keith LeonardCEOSell13,260$39.08$518,200.80View SEC Filing  
3/20/2014John SmitherCFOSell1,125$43.78$49,252.5010,200View SEC Filing  
3/3/2014Jeffrey WebsterVPSell4,000$49.55$198,200.00View SEC Filing  
3/3/2014Nathaniel DavidDirectorSell5,099$49.18$250,768.82497,285View SEC Filing  
2/20/2014John SmitherCFOSell2,250$49.75$111,937.5010,200View SEC Filing  
2/14/2014John SmitherCFOSell1,125$50.00$56,250.0010,200View SEC Filing  
2/3/2014Jeffrey WebsterVPSell4,000$45.40$181,600.00View SEC Filing  
2/3/2014Keith LeonardCEOSell12,740$45.35$577,759.0052,452View SEC Filing  
2/3/2014Nathaniel DavidDirectorSell5,000$45.31$226,550.00502,384View SEC Filing  
1/21/2014John SmitherCFOSell1,125$42.54$47,857.5010,200View SEC Filing  
1/2/2014Jeffrey WebsterVPSell4,000$37.38$149,520.00View SEC Filing  
1/2/2014Keith LeonardCEOSell12,480$37.38$466,502.404,461View SEC Filing  
12/2/2013Jeffrey WebsterVPSell4,000$38.69$154,760.00View SEC Filing  
12/2/2013Keith LeonardCEOSell12,220$38.95$475,969.00View SEC Filing  
12/2/2013Nathaniel DavidDirectorSell4,800$38.72$185,856.00512,286View SEC Filing  
11/1/2013Jeffrey D WebsterVPSell4,000$44.90$179,600.00View SEC Filing  
11/1/2013Keith R LeonardCEOSell11,960$44.22$528,871.20View SEC Filing  
11/1/2013Nathaniel E DavidDirectorSell4,698$43.93$206,383.14View SEC Filing  
9/16/2013Keith LeonardCEOSell2,860$33.62$96,153.20View SEC Filing  
9/10/2013John W SmitherCFOSell40,000$30.02$1,200,800.00View SEC Filing  
9/10/2013Keith KleinGeneral CounselSell4,500$32.00$144,000.00View SEC Filing  
9/10/2013Nathaniel E DavidDirectorSell6,376$31.00$197,656.00View SEC Filing  
9/3/2013Jeffrey WebsterVPSell4,000$26.11$104,440.00View SEC Filing  
9/3/2013Keith LeonardCEOSell8,580$26.12$224,109.60View SEC Filing  
9/3/2013Nathaniel DavidDirectorSell3,375$26.12$88,155.00532,760View SEC Filing  
8/1/2013Jeffrey D WebsterVPSell4,000$26.76$107,040.00View SEC Filing  
8/1/2013John W SmitherCFOSell10,000$26.80$268,000.00View SEC Filing  
8/1/2013Keith R LeonardCEOSell8,385$26.73$224,131.05View SEC Filing  
8/1/2013Nathaniel E DavidDirectorSell3,301$26.76$88,334.76View SEC Filing  
7/15/2013Keith R LeonardCEOSell1,365$28.90$39,448.50View SEC Filing  
7/1/2013Jeffrey D WebsterVPSell4,000$27.06$108,240.00View SEC Filing  
7/1/2013Keith R LeonardCEOSell8,190$27.10$221,949.00View SEC Filing  
7/1/2013Nathaniel E DavidDirectorSell3,225$27.07$87,300.75View SEC Filing  
6/28/2013Keith KleinGeneral CounselSell4,500$27.00$121,500.00View SEC Filing  
6/17/2013John W SmitherCFOSell6,000$26.00$156,000.00View SEC Filing  
6/17/2013Keith R LeonardCEOSell1,332$25.69$34,219.08View SEC Filing  
6/17/2013Nathaniel E DavidDirectorSell1,538$26.00$39,988.00View SEC Filing  
6/7/2013Jeffrey D WebsterVPSell4,000$25.00$100,000.00View SEC Filing  
6/3/2013Keith R LeonardCEOSell6,663$21.25$141,588.75View SEC Filing  
5/31/2013Jeffrey D WebsterVPSell4,000$22.26$89,040.00View SEC Filing  
5/1/2013Nathaniel E DavidDirectorSell2,625$21.42$56,227.50View SEC Filing  
(Data available from 1/1/2013 forward)


Kythera Biopharmaceuticals (NASDAQ KYTH) News Headlines

Unity Biotechnology Finalizes $85 Million IPO TermsUnity Biotechnology Finalizes $85 Million IPO Terms - April 23 at 4:02 PM
Pulmatrix (PULM) Appoints Amit Munshi to BoardPulmatrix (PULM) Appoints Amit Munshi to Board - June 16 at 7:14 AM
Pulmatrix (PULM) Appoints Amit Munshi to BoardPulmatrix (PULM) Appoints Amit Munshi to Board - June 16 at 7:14 AM
Amit D. Munshi Joins Pulmatrixs Board of DirectorsAmit D. Munshi Joins Pulmatrix's Board of Directors - June 16 at 7:14 AM
Amit D. Munshi Joins Pulmatrixs Board of DirectorsAmit D. Munshi Joins Pulmatrix's Board of Directors - June 16 at 7:14 AM
Neothetics: A Look Ahead - Seeking AlphaNeothetics: A Look Ahead - Seeking Alpha - December 22 at 12:47 AM
Neothetics: A Look AheadNeothetics: A Look Ahead - December 21 at 7:03 PM
Nohla Therapeutics Announces Closing of $43.5M Series A Financing to Transform Stem Cell Transplantation with ... - GlobeNewswire (press release)Nohla Therapeutics Announces Closing of $43.5M Series A Financing to Transform Stem Cell Transplantation with ... - GlobeNewswire (press release) - November 30 at 6:21 PM
6 Reasons to Watch Kythera Biopharm Inc. (AGN, PFE)6 Reasons to Watch Kythera Biopharm Inc. (AGN, PFE) - November 19 at 8:28 AM
Alder BioPharmaceuticals (ALDR) CEO Randy Schatzman on Q3 ... - Seeking AlphaAlder BioPharmaceuticals' (ALDR) CEO Randy Schatzman on Q3 ... - Seeking Alpha - October 28 at 9:25 AM
Anti-Aging Startup Raises $116 Million With Bezos Backing - BloombergAnti-Aging Startup Raises $116 Million With Bezos Backing - Bloomberg - October 28 at 9:25 AM
BlackThorn Therapeutics Launches to Develop Novel, Targeted Treatments for Neurobehavioral Disorders - Business Wire (press release)BlackThorn Therapeutics Launches to Develop Novel, Targeted Treatments for Neurobehavioral Disorders - Business Wire (press release) - October 20 at 11:34 AM
Pfenex Inc. Announces Formation of Scientific Advisory Board - PR Newswire (press release)Pfenex Inc. Announces Formation of Scientific Advisory Board - PR Newswire (press release) - October 20 at 11:34 AM
Medical Aesthetics Market Worth $69,786 Million by 2021Medical Aesthetics Market Worth $69,786 Million by 2021 - August 10 at 8:52 AM
MannKind (MNKD) Assumes Responsibility for Distribution of Afrezza; Launches Patient Reimbursement Programs - StreetInsider.comMannKind (MNKD) Assumes Responsibility for Distribution of Afrezza; Launches Patient Reimbursement Programs - - August 1 at 5:45 PM
Sienna Biopharmaceuticals Announces Second Closing of Series A Financing - Business Wire (press release)Sienna Biopharmaceuticals Announces Second Closing of Series A Financing - Business Wire (press release) - July 13 at 6:17 PM

SEC Filings

Kythera Biopharmaceuticals (NASDAQ:KYTH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Kythera Biopharmaceuticals (NASDAQ:KYTH) Income Statement, Balance Sheet and Cash Flow Statement


Kythera Biopharmaceuticals (NASDAQ KYTH) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.